JP2016531843A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016531843A5 JP2016531843A5 JP2016515394A JP2016515394A JP2016531843A5 JP 2016531843 A5 JP2016531843 A5 JP 2016531843A5 JP 2016515394 A JP2016515394 A JP 2016515394A JP 2016515394 A JP2016515394 A JP 2016515394A JP 2016531843 A5 JP2016531843 A5 JP 2016531843A5
- Authority
- JP
- Japan
- Prior art keywords
- cd1a
- inhibitor
- activity
- pharmaceutical composition
- inflammatory skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000694 effects Effects 0.000 claims 14
- 239000003112 inhibitor Substances 0.000 claims 14
- 201000004624 Dermatitis Diseases 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 239000003446 ligand Substances 0.000 claims 7
- RMTXUPIIESNLPW-UHFFFAOYSA-N 1,2-dihydroxy-3-(pentadeca-8,11-dienyl)benzene Natural products CCCC=CCC=CCCCCCCCC1=CC=CC(O)=C1O RMTXUPIIESNLPW-UHFFFAOYSA-N 0.000 claims 5
- QARRXYBJLBIVAK-UEMSJJPVSA-N 3-[(8e,11e)-pentadeca-8,11-dienyl]benzene-1,2-diol;3-[(8e,11e)-pentadeca-8,11,14-trienyl]benzene-1,2-diol;3-[(8e,11e,13e)-pentadeca-8,11,13-trienyl]benzene-1,2-diol;3-[(e)-pentadec-8-enyl]benzene-1,2-diol;3-pentadecylbenzene-1,2-diol Chemical group CCCCCCCCCCCCCCCC1=CC=CC(O)=C1O.CCCCCC\C=C\CCCCCCCC1=CC=CC(O)=C1O.CCC\C=C\C\C=C\CCCCCCCC1=CC=CC(O)=C1O.C\C=C\C=C\C\C=C\CCCCCCCC1=CC=CC(O)=C1O.OC1=CC=CC(CCCCCCC\C=C\C\C=C\CC=C)=C1O QARRXYBJLBIVAK-UEMSJJPVSA-N 0.000 claims 5
- IYROWZYPEIMDDN-UHFFFAOYSA-N 3-n-pentadec-8,11,13-trienyl catechol Natural products CC=CC=CCC=CCCCCCCCC1=CC=CC(O)=C1O IYROWZYPEIMDDN-UHFFFAOYSA-N 0.000 claims 5
- 210000001821 langerhans cell Anatomy 0.000 claims 5
- DQTMTQZSOJMZSF-UHFFFAOYSA-N urushiol Natural products CCCCCCCCCCCCCCCC1=CC=CC(O)=C1O DQTMTQZSOJMZSF-UHFFFAOYSA-N 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 208000017520 skin disease Diseases 0.000 claims 4
- 150000003384 small molecules Chemical class 0.000 claims 4
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 3
- 230000030741 antigen processing and presentation Effects 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 230000009368 gene silencing by RNA Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000012385 systemic delivery Methods 0.000 claims 2
- 238000012384 transportation and delivery Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361880522P | 2013-09-20 | 2013-09-20 | |
| US61/880,522 | 2013-09-20 | ||
| PCT/US2014/056021 WO2015042110A1 (en) | 2013-09-20 | 2014-09-17 | Treatment of inflammatory skin disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016531843A JP2016531843A (ja) | 2016-10-13 |
| JP2016531843A5 true JP2016531843A5 (enExample) | 2017-11-02 |
Family
ID=52689337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016515394A Pending JP2016531843A (ja) | 2013-09-20 | 2014-09-17 | 炎症性皮膚疾患の治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10844118B2 (enExample) |
| EP (2) | EP3046629A4 (enExample) |
| JP (1) | JP2016531843A (enExample) |
| CA (1) | CA2924882A1 (enExample) |
| WO (1) | WO2015042110A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL280880B2 (en) | 2018-08-27 | 2025-04-01 | Regeneron Pharma | Using Raman Spectroscopy in Downstream Purification |
| AU2021358662A1 (en) * | 2020-10-09 | 2023-05-04 | Children's Medical Center Corporation | CD1a ANTIBODIES AND USES THEREOF |
| US20240383986A1 (en) | 2021-05-26 | 2024-11-21 | Oxford University Innovation Limited | Antibodies |
| GB202217923D0 (en) | 2022-11-29 | 2023-01-11 | Univ Oxford Innovation Ltd | Antibodies |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206347A (en) | 1985-08-06 | 1993-04-27 | La Jolla Cancer Research Foundation | Isolation and use of receptors binding to a peptide column |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5264563A (en) | 1990-08-24 | 1993-11-23 | Ixsys Inc. | Process for synthesizing oligonucleotides with random codons |
| US5622699A (en) | 1995-09-11 | 1997-04-22 | La Jolla Cancer Research Foundation | Method of identifying molecules that home to a selected organ in vivo |
| US20010051156A1 (en) | 2000-04-28 | 2001-12-13 | Defu Zeng | Methods for inhibition of polyclonal B cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking CD1-mediated interactions |
| WO2004093903A2 (en) * | 2003-04-18 | 2004-11-04 | The Brigham And Women's Hospital, Inc. | Methods and compositions for immunomodulation using cd1 antigens |
| JP4712724B2 (ja) * | 2003-12-23 | 2011-06-29 | クルセル ホランド ベー ヴェー | ＣＤ１ａに対するヒト結合分子 |
| US20090203586A1 (en) | 2004-06-11 | 2009-08-13 | Syngenta Limited | Method for ameliorating an inflammatory skin condition |
| US20070059268A1 (en) * | 2005-09-09 | 2007-03-15 | Laura Magee | Compositions, methods and kits for treating allergic dermatitis of skin |
-
2014
- 2014-09-17 JP JP2016515394A patent/JP2016531843A/ja active Pending
- 2014-09-17 CA CA2924882A patent/CA2924882A1/en not_active Abandoned
- 2014-09-17 WO PCT/US2014/056021 patent/WO2015042110A1/en not_active Ceased
- 2014-09-17 US US15/023,283 patent/US10844118B2/en not_active Expired - Fee Related
- 2014-09-17 EP EP14846174.2A patent/EP3046629A4/en not_active Withdrawn
- 2014-09-17 EP EP18205026.0A patent/EP3461535A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Qi et al. | From COPD to lung cancer: mechanisms linking, diagnosis, treatment, and prognosis | |
| Rynkeviciene et al. | Non-coding RNAs in glioma | |
| Sun et al. | Cellular senescence: the sought or the unwanted? | |
| Liberale et al. | Pathophysiological relevance of macrophage subsets in atherogenesis | |
| Aghaei et al. | The ER stress/UPR axis in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis | |
| Diling et al. | Circular RNA NF1-419 enhances autophagy to ameliorate senile dementia by binding Dynamin-1 and Adaptor protein 2 B1 in AD-like mice | |
| Lee et al. | Regulation of tumor progression by programmed necrosis | |
| Giatromanolaki et al. | Autophagy and lysosomal related protein expression patterns in human glioblastoma | |
| Mongiardi et al. | Cancer response to therapy-induced senescence: A matter of dose and timing | |
| Yong et al. | Ribosomal proteins RPS11 and RPS20, two stress-response markers of glioblastoma stem cells, are novel predictors of poor prognosis in glioblastoma patients | |
| Wang et al. | Overexpression of high mobility group box 1 and 2 is associated with the progression and angiogenesis of human bladder carcinoma | |
| Savva et al. | Recent advancements in the atopic dermatitis mechanism | |
| Kessler et al. | The molecular fingerprint of high grade serous ovarian cancer reflects its fallopian tube origin | |
| Ashby et al. | Distribution profiling of circulating microRNAs in serum | |
| Chen et al. | IL-17–induced HIF1α drives resistance to anti–PD-L1 via fibroblast-mediated immune exclusion | |
| Li et al. | LncTRPM2-AS inhibits TRIM21-mediated TRPM2 ubiquitination and prevents autophagy-induced apoptosis of macrophages in asthma | |
| Sałkowska et al. | Differentiation stage-specific effect of histone deacetylase inhibitors on the expression of RORγT in human lymphocytes | |
| Jena et al. | Type III interferons induce pyroptosis in gut epithelial cells and impair mucosal repair | |
| JP2016531843A5 (enExample) | ||
| Li et al. | An updated review of the epigenetic mechanism underlying the pathogenesis of age-related macular degeneration | |
| Tsolou et al. | ‘Stemness’ and ‘senescence’related escape pathways are dose dependent in lung cancer cells surviving post irradiation | |
| Frąszczak et al. | The role of cancer stem cell markers in ovarian cancer | |
| Li et al. | Exosomal miR-93-5p regulated the progression of osteoarthritis by targeting ADAMTS9 | |
| Wang et al. | Nuclear complement C3b promotes paclitaxel resistance by assembling the SIN3A/HDAC1/2 complex in non-small cell lung cancer | |
| Arnhold et al. | Corticosteroids impair epithelial regeneration in immune-mediated intestinal damage |